Pregabalin in the management of partial epilepsy

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 407-413

  Arain, Amir M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; PHENYTOIN; PLACEBO; PREGABALIN; VALPROIC ACID; VENLAFAXINE; VOLTAGE GATED CALCIUM CHANNEL;

ABNORMAL THINKING; ADJUVANT THERAPY; ADL DISABILITY; AGGRESSION; AGITATION; AMBLYOPIA; ANTICONVULSANT ACTIVITY; ASTHENIA; ATAXIA; BEHAVIOR DISORDER; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DAYTIME SOMNOLENCE; DEPRESSION; DIABETIC NEUROPATHY; DIPLOPIA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG APPROVAL; DRUG CHOICE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INDUCTION; FIBROMYALGIA; FOCAL EPILEPSY; GENERALIZED ANXIETY DISORDER; HUMAN; INTELLECTUAL IMPAIRMENT; INTRACTABLE EPILEPSY; IRRITABILITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; MULTIPLE DRUG DOSE; MYOCLONUS; NEUROPATHIC PAIN; NOTE; PAIN; POLYSOMNOGRAPHY; POSTHERPETIC NEURALGIA; POSTMARKETING SURVEILLANCE; PRESYNAPTIC NERVE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; VERTIGO; WEIGHT GAIN;

EID: 70449723707     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s3850     Document Type: Note

References (39)

1. Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry. 1996;61(5):433-443.
2. Arain A. Medical therapy of epilepsy. Expert Opin Ther Pat. 2007;17(8):955-964.
3. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314-319.
4. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ. 1996;313(7066):1169-1174. (Pubitemid 26381894)
5. Vartanian MG, Radulovic LL, Kinsora JJ, et al. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 2006;68(3):189-205.
6. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73(2):137-150. (Pubitemid 46329329)
7. Dooley DJ, Donovan CM, Meder WP, Whetzel SZ. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse. 2002;45(3):171-190.
8. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2(8):473-481. (Pubitemid 36876104)
9. Harden CL, Leppik I. Optimizing therapy of seizures in women who use oral contraceptives. Neurology. 2006;67(12 Suppl 4):S56-S58. (Pubitemid 44968000)
10. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246-255. (Pubitemid 43382623)
11. Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia. 2005;46(9):1407-1413.
12. May TW, Rambeck B, Neb R, Jurgens U. Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2007;29(6):789-794. (Pubitemid 350190856)
13. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet. 2006;45(11):1061-1075. (Pubitemid 44631387)
14. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43(3):277-283. (Pubitemid 36232656)
15. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology. 2003;60(10):1631-1637. (Pubitemid 36618090)
16. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004;45(1):20-27. (Pubitemid 38063660)
17. Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology. 2005;64(3):475-480. (Pubitemid 40189866)
18. Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia. 2005;46(12):1926-1936. (Pubitemid 44922003)
19. Lozsadi D, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2008(1):CD005612. (Pubitemid 351807664)
20. Ryvlin P, Perucca E, Rheims S. Pregabalin for the management of partial epilepsy. Neuropsychiatr Dis Treat. 2008;4(6):1211-1224.
21. Warner G, Figgitt DP. Pregabalin: as adjunctive treatment of partial seizures. CNS Drugs. 2005;19(3):265-272; discussion 273-1264 (Pubitemid 40460665)
22. Brodie MJ. Pregabalin as adjunctive therapy for partial seizures. Epilepsia. 2004;45 Suppl 6:19-27.
23. Vera-Llonch M, Brandenburg NA, Oster G. Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy. Epilepsia. 2008;49(3):431-437. (Pubitemid 351294524)
24. Gil-Nagel A, Zaccara G, Baldinetti F, Leon T. Add-on treatment with pregabalin for partial seizures with or without generalisation: Pooled data analysis of four randomised placebo-controlled trials. Seizure. 2009;18(3):184-192.
25. Hoppe C, Rademacher M, Hoffmann JM, Schmidt D, Elger CE. Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients? Seizure. 2008;17(4):327-332. (Pubitemid 351615300)
26. Arain A, Shihabuddin B, Niaz F, et al. Epilepsy and the impact of an epileptology clinic for patients with mental retardation and associated disabilities in an institutional setting. Epilepsia. 2006;47(12):2052-2057. (Pubitemid 44952257)
27. Modur PN, Milteer WE. Adjunctive pregabalin therapy in mentally retarded, developmentally delayed patients with epilepsy. Epilepsy Behav. 2008;13(3):554-556.
28. Huber B, Bocchicchio M, Feuerbaum E, et al. Efficacy and tolerability of pregabalin in patients with difficult-to-treat epilepsy and intellectual disability. Epilepsy Behav. 2008;13(2):397-401.
29. Seeley JM, Mrelashvili D, Gallagher MJ, Arain A, Abou-Khalil B. Pregabalin efficacy and tolerability in patients with intractable partial seizures. A postmarketing analysis. Epilepsia. 2007;48(s6):320-321.
30. Kubota T, Fang J, Meltzer LT, Krueger JM. Pregabalin enhances nonrapid eye movement sleep. J Pharmacol Exp Ther. 2001;299(3):1095-1105. (Pubitemid 33104981)
31. Romigi A, Izzi F, Marciani MG, et al. Pregabalin as add-on therapy induces REM sleep enhancement in partial epilepsy: a polysomnographic study. Eur J Neurol. 2009;16(1):70-75.
32. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008;22(1):27-47. (Pubitemid 350243365)
33. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63(11):2104-2110. (Pubitemid 39636259)
34. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60(8):1274-1283. (Pubitemid 36460982)
35. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35(3):502-514.
36. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006;67(5):771-782. (Pubitemid 43946184)
37. Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia. 2001;42(6):790-792. (Pubitemid 32605944)
38. Beydoun A, Nasreddine W, Atweh S. Efficacy and tolerability of pregabalin in partial epilepsy. Expert Rev Neurother. 2008;8(7):1013-1024. (Pubitemid 351962069)
39. Mensah SA, Beavis JM, Thapar AK, Kerr MP. A community study of the presence of anxiety disorder in people with epilepsy. Epilepsy Behav. 2007;11(1):118-124.